JMP reiterates MedImmune at market perform

MedImmune Inc. was reiterated by JMP Securities LLC analyst Adam Cutler at a market perform rating after third-quarter results showed total revenue of $153.6 million beat JMP's estimates of $111.4 million. Revenue was driven by the stocking of Synagis for RSV season, but it was offset by higher-than-expected research and development expenses due to payments related to collaborations. Shares of the Gaithersburg, Md., biotechnology company were down $0.49, or 1.45%, at $33.26 on volume of 2,951,439 shares versus the three-month running average of 2,730,320 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.